Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

v3.2.0.727
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Condensed Consolidated Statements Of Operations        
Revenues, net $ 457,780 $ 238,008 $ 733,245 $ 368,837
Operating expenses:        
Cost of implants and other costs 108,750 47,262 120,250 74,962
Selling, general and administrative 465,325 $ 604,604 703,393 $ 1,065,459
Termination of licensing agreement 3,639,694   3,639,694  
Loss on settlement of sub-licenses 118,027   118,027  
Depreciation and amortization 33,723 $ 33,947 67,289 $ 67,947
Total operating expenses 4,365,519 685,813 4,648,653 1,208,368
Net loss from operations (3,907,739) (447,805) (3,915,408) (839,531)
Other income (expenses):        
Interest expense, net (62,805) (128,845) (162,654) (202,022)
Gain on change in fair value of derivative liability 199,824 916,232 104,168 304,950
(Loss) income before income taxes $ (3,770,720) $ 339,582 $ (3,973,894) $ (736,603)
Income taxes        
Net (loss) income $ (3,770,720) $ 339,582 $ (3,973,894) $ (736,603)
Net (loss) income per common share, basic $ (0.02) $ 0 $ (0.03) $ (0.01)
Net (loss) income per common share, diluted $ (0.02) $ 0 $ (0.03) $ (0.01)
Weighted average number of common shares outstanding, basic 151,757,578 137,223,842 150,453,147 133,043,009
Weighted average number of common shares outstanding, diluted 151,757,578 141,999,123 105,453,147 133,043,009